FINWIRES · TerminalLIVE
FINWIRES

SHA:603392

6 stories mentioning SHA:603392Updated 16d ago

Every FINWIRES story that references SHA:603392, newest first.

Asia

Wantai Biological Gets China NMPA Approval for Respiratory Syncytial Virus Vaccine

Beijing Wantai Biological Pharmacy Enterprise (SHA:603392) received approval from China's National Medical Products Administration for its self-developed freeze-dried recombinant respiratory syncytial virus vaccine, according to a Tuesday filing with the Shanghai bourse.The vaccine prevents lower respiratory tract disease caused by respiratory syncytial virus in vulnerable populations such as the elderly and those with chronic diseases.

SHA:603392
Asia

Wantai Biological Applies for Marketing Authorization in China for Varicella Live Vaccine

China's drug regulator accepted Beijing Wantai Biological Pharmacy Enterprise's (SHA:603392) marketing authorization application for its varicella live attenuated vaccine.The National Medical Products Administration will evaluate the safety, efficacy, and quality of the vaccine, according to a Thursday disclosure to the Shanghai bourse.

SHA:603392
Asia

Wantai Biological Pharmacy Enterprise Submits WHO Prequalification Application for HPV Vaccine

Beijing Wantai Biological Pharmacy Enterprise (SHA:603392) subsidiary Wantai Canghai has submitted a prequalification application with the World Health Organization for its nine-valent human papillomavirus (HPV) vaccine, according to a Tuesday filing with the Shanghai bourse.Shares of the drugmaker declined 2% in recent trade.

SHA:603392
Asia

Wantai Biological Pharmacy HPV Vaccine Gains Nationwide Access; Shares Up 5%

Beijing Wantai Biological Pharmacy Enterprise (SHA:603392) announced that its nine-valent human papillomavirus (HPV) vaccine, Cecolin 9, has completed market access across the 31 provinces, autonomous regions and municipalities in China, excluding Hong Kong, Macao and Taiwan.The vaccine has entered about 2,300 CDC centers and covers about 13,000 vaccination points nationwide, according to a Sunday filing with the Shanghai bourse.Shares of the drugmaker rose nearly 5% in recent trade.

SHA:603392
Asia

Wantai Biological Pharmacy Narrows Q1 Loss; Shares Fall 3%

Beijing Wantai Biological Pharmacy Enterprise (SHA:603392) posted first-quarter attributable net loss of 43 million yuan, compared with 53 million yuan the previous year.Loss per share narrowed to 0.03 yuan from 0.04 yuan, according to a Tuesday filing with the Shanghai bourse.Revenue rose 31% year over year to 523 million yuan from 401 million yuan.Shares of the drug manufacturer were down 3% in recent trade.

SHA:603392
Asia

Wantai Biological Swings to Loss in 2025; Shares Fall 4%

Beijing Wantai Biological Pharmacy Enterprise (SHA:603392) swung to an attributable loss of 398.3 million yuan in 2025 from an attributable profit of 106.2 million yuan in 2024, according to a Tuesday filing with the Shanghai bourse.The drug manufacturer logged a loss per share of 0.31 yuan compared with earnings per share of 0.08 yuan in the previous year.Operating income declined 19% year over year to 1.82 billion yuan from 2.25 billion yuan.Shares decreased 4% during morning trading on Tuesday.

SHA:603392

Track with the FINWIRES app suite

FolioX
FolioX
Track SHA:603392 in your portfolio
WheelAI
WheelAI
Analyze SHA:603392 options with the wheel strategy
StockInsider
StockInsider
See market sentiment on SHA:603392